Factors Associated With Cancer Treatment Delay Among Patients Diagnosed With COVID-19

Authors:

Abstract
As a result of system- and patient-level factors related to the COVID-19 pandemic, cancer care has frequently been delayed or altered. For example, recent data showed that half of European breast centers altered systemic treatments during the pandemic and one-fifth of patients experienced delay in radiation therapy.1 Professional societies quickly released guidance to amend care guidelines during a time of great uncertainty, prior to vaccines and other therapies.2-6 These guidelines helped clinicians prioritize patients with higher-risk disease to avoid treatment delays and suggested alternatives, such as beginning systemic therapy first to permit surgical treatment to be delayed.7,8 Changes to conventional treatment plans have subsequently been studied for associations with outcomes.9,10 Such studies help researchers identify cancers and clinical settings in which delays are not associated with overall survival, as well as situations in which delays in treatment truly are harmful.11 However, these studies have largely assessed the impact of the pandemic among patients with cancer who did not contract COVID-19 themselves.

This publication has 23 references indexed in Scilit: